TherapeuticsMD Announces Fourth Quarter and Full-Year 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Noble Financial Lifts PT on TherapeuticsMD (TXMD) to $15; Sees Reduced TX 12-001HR Risk
March 11, 2015 11:47 AM EDTNoble Financial affirms TherapeuticsMD, Inc. (AMEX: TXMD) at Buy and nudges its price target from $14 up to $15 following Q4 results and update issued after markets closed Tuesday.
Analyst Nathan Cali noted that the bump higher in TXMD's price target stems from an increased cash balance, lowering the cost of capital by 5 points to 15 percent, and increasing risk-adjusted rNPV for TX 12-001HR, bioidentical estradiol/progesterone.
Cali also noted the following key points from the quarter and recent updates:
March 10th, 2015 reported relatively inline full year 2015 financial... MoreTherapeuticsMD (TXMD) Reports Q4 Loss of $0.10/Share
March 10, 2015 4:11 PM EDTTherapeuticsMD (NYSE: TXMD) reported Q4 EPS of ($0.10), versus ($0.06) reported last year. Revenue for the quarter came in at $4.26 million, versus $2.86 million reported last year.
For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.
... More